Mezzion Pharma announces that it has conducted a Type C Meeting with the FDA Regarding the TOP Line Data from the FUEL Phase 3 Clinical Trial

SEOUL, South Korea, Oct. 10, 2019 /PRNewswire/ -- Mezzion Pharma Co. Ltd. (140410: KOSDAQ) today announces that on Tuesday, October 8, 2019, Mezzion conducted the Type C meeting with the FDA in Silver Spring, Maryland. The purpose of the Type C meeting was to receive FDA guidance on...

from PR Newswire: https://ift.tt/2IDt6m8